Any woman who has frozen her eggs or undergone in vitro fertilization (IVF) to try and get pregnant knows how challenging and time consuming the process can be. This is something Gameto’s CEO and co-founder Dina Radenkovic Turner, MD, is trying to change.

The company’s lead candidate treatment Fertilo is currently in Phase III trials in the U.S. and already has approval in several other countries. It aims to cut the time needed for ovarian stimulation and egg collection from two weeks to a few days by using engineered ovarian support cells to mature the eggs outside the body. In addition, the company plans to develop treatments for menopause and ovarian disease.

Gameto has raised a total of $127 million in a difficult funding climate, with Fertilo being the first induced pluripotent stem

See Full Page